[{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ADX71149","moa":"Metabotropic glutamate receptor type 2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"ADX10061","moa":"D1 receptor","graph1":"Neurology","graph2":"Discovery","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Innosuisse","highestDevelopmentStatusID":"2","companyTruncated":"Addex Therapeutics \/ Innosuisse"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA-B","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Addex Therapeutics","amount2":0.33000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0.33000000000000002,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior PLC","highestDevelopmentStatusID":"2","companyTruncated":"Addex Therapeutics \/ Indivior PLC"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Dipraglurant","moa":"mGlu5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ADX71149","moa":"Metabotropic glutamate receptor type 2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ADX71149","moa":"Metabotropic glutamate receptor type 2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"INDV-1000","moa":"GABA B receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"The Charcot\u2013Marie\u2013Tooth Association","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA B receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ The Charcot\u2013Marie\u2013Tooth Association","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ The Charcot\u2013Marie\u2013Tooth Association"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dipraglurant","moa":"mGlu5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ADX71149","moa":"Metabotropic glutamate receptor type 2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Janssen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Janssen Pharmaceuticals"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dipraglurant","moa":"mGlu5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dipraglurant","moa":"mGlu5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund LTV","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Dipraglurant","moa":"mGlu5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Armistice Master Fund LTV","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Armistice Master Fund LTV"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Dipraglurant","moa":"mGlu5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Armistice Master Fund Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Armistice Master Fund Ltd."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA B receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0.34000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ADX71149","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Addex Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Addex Therapeutics"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"ADX71149","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dipraglurant","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"JNJ-40411813","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Addex Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0.34000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ADX71149","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Addex Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Naason Science","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Naason Science","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Naason Science"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ADX71149","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ADX71149","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Addex Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ADX71149","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Addex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Addex Therapeutics","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"12","companyTruncated":"Addex Therapeutics \/ Indivior"}]
Find Clinical Drug Pipeline Developments & Deals by Addex Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
